1700001C19Rik Inhibitors
Chemical inhibitors of 1700001C19Rik can impact its function via various mechanisms related to intracellular signaling pathways. Staurosporine, a well-known kinase inhibitor, can indiscriminately inhibit a wide range of kinases, which may include those that phosphorylate 1700001C19Rik, thus preventing its activation or modifying its activity. Another inhibitor, Bisindolylmaleimide I, has a more selective action, targeting protein kinase C (PKC). Since PKC may be involved in the phosphorylation of 1700001C19Rik, its inhibition by Bisindolylmaleimide I can affect the protein's functional activity. LY294002 and Wortmannin both act on the PI3K/Akt pathway by inhibiting PI3K, which could result in a downregulation of downstream effects, including those on 1700001C19Rik. Similarly, PD98059 and U0126 target the MAPK/ERK pathway by inhibiting MEK, which could reduce the phosphorylation and subsequent activity of proteins within this pathway, including 1700001C19Rik.
The JNK pathway inhibitor SP600125 and the p38 MAP kinase inhibitor SB203580 can also alter the function of 1700001C19Rik by modulating the activity of proteins regulated by these MAPK pathways. Rapamycin, which inhibits mTOR, can lead to a reduction in the activity of proteins involved in the mTOR signaling pathway, impacting the function of 1700001C19Rik. PP2, which inhibits Src family kinases, can decrease the activation of kinases that may phosphorylate 1700001C19Rik, affecting its activity. Dasatinib, another tyrosine kinase inhibitor, can block BCR-ABL and Src family kinases, potentially leading to the inhibition of 1700001C19Rik's activation and function. Lastly, Y-27632 targets the Rho/ROCK pathway by inhibiting ROCK kinase, which can affect the activity of downstream proteins within this pathway, including 1700001C19Rik. These chemical inhibitors collectively can influence the activity and regulation of 1700001C19Rik by targeting various kinases and pathways that are upstream of its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is an ATP-competitive kinase inhibitor that can inhibit a broad range of kinases that may phosphorylate 1700001C19Rik, leading to its functional inhibition by preventing its activation or the modification of its activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I selectively inhibits protein kinase C, which could be involved in the phosphorylation of 1700001C19Rik, and by inhibiting this kinase, the chemical can inhibit the functional activity of 1700001C19Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which participates in the Akt signaling pathway. By inhibiting PI3K, LY294002 can inhibit downstream effects that might include the functional regulation of 1700001C19Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can prevent activation of downstream targets within the PI3K/Akt pathway, potentially inhibiting the function of 1700001C19Rik by preventing necessary phosphorylation events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is involved in the MAPK/ERK pathway. By inhibiting MEK, PD98059 can inhibit the phosphorylation and activation of proteins within this pathway, potentially including 1700001C19Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream of the ERK pathway. Inhibition of MEK by U0126 can lead to a reduction in ERK pathway activity, potentially inhibiting the functional activity of 1700001C19Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathway. Inhibiting JNK can lead to decreased activity of proteins regulated by this pathway, potentially including the functional inhibition of 1700001C19Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which can modulate stress responses and inflammation. Inhibition of p38 by SB203580 could lead to the inhibition of downstream proteins, potentially including 1700001C19Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR by forming a complex with FKBP12, which can reduce the activity of proteins involved in the mTOR signaling pathway, potentially leading to the functional inhibition of 1700001C19Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor that can decrease activation of certain kinases. Inhibition of these kinases by PP2 could lead to decreased activity of proteins like 1700001C19Rik, if they are downstream targets. | ||||||